Article ; Online: Evaluation of human epididymal secretory protein 4 expression according to the molecular subtypes (luminal A, luminal B, human epidermal growth factor receptor 2-positive, triple-negative) of breast cancer.
Indian journal of pathology & microbiology
2018 Volume 61, Issue 3, Page(s) 323–329
Abstract: Background/aims: Human epididymal secretory protein 4 (HE4) is originally described as an epididymis-specific protein but more recently suggested to be a putative serum tumor marker for some tumors, including breast carcinomas. In this study, we aimed ... ...
| Abstract | Background/aims: Human epididymal secretory protein 4 (HE4) is originally described as an epididymis-specific protein but more recently suggested to be a putative serum tumor marker for some tumors, including breast carcinomas. In this study, we aimed to investigate the interactions between HE4 expression and molecular subtypes of breast carcinomas. Methods: HE4 expressions were studied in 242 formalin-fixed, paraffin-embedded breast carcinoma specimens and their association with different pathological and clinical parameters was evaluated. Results: Immunohistochemical (IHC) staining for HE4 was negative in 3 (1.2%) cases, weakly positive (1+) in 7 (2.9%) cases, moderately positive (2+) in 58 (24.0%) cases, and strongly positive (3+) in 174 (71.9%) cases. A correlation between IHC HE4 staining grade and molecular groups was detected (P = 0.005). Furthermore, it was found that HE4 expression was strongly associated with histological tumor grade, c-erbB2 expression, and positive fluorescence in situ hybridization test results that detect human epidermal growth factor receptor 2 (HER2)/neu amplification (P = 0.022, P = 0.014, and P = 0.011). Conclusion: This study showed that HE4 expression is associated with HER2/neu amplification in breast cancers. These results may be commented as HE4 expression rises in patients with HER2/neu amplification. As is known, HER2/neu amplification is a poor diagnostic factor in breast cancer and HE4 expression is possibly associated with poor prognosis. |
|---|---|
| MeSH term(s) | Adult ; Aged ; Biomarkers, Tumor ; Breast Neoplasms/classification ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Female ; Genes, erbB-2/genetics ; Humans ; Immunohistochemistry ; In Situ Hybridization, Fluorescence/methods ; Middle Aged ; Proteins/genetics ; Receptor, ErbB-2/genetics ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/pathology ; WAP Four-Disulfide Core Domain Protein 2 |
| Chemical Substances | Biomarkers, Tumor ; Proteins ; WAP Four-Disulfide Core Domain Protein 2 ; WFDC2 protein, human ; ERBB2 protein, human (EC 2.7.10.1) ; Receptor, ErbB-2 (EC 2.7.10.1) |
| Language | English |
| Publishing date | 2018-07-13 |
| Publishing country | India |
| Document type | Evaluation Study ; Journal Article |
| ZDB-ID | 197621-7 |
| ISSN | 0974-5130 ; 0377-4929 |
| ISSN (online) | 0974-5130 |
| ISSN | 0377-4929 |
| DOI | 10.4103/IJPM.IJPM_465_17 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 862: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.